SBH
CSTL icon

Segall Bryant & Hamill’s Castle Biosciences CSTL Stock Holding History

Segall Bryant & Hamill’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-202,344
Closed -$5.28M – 717
2022
Q3 		$5.28M Buy
202,344
+4,030
+2% +$113K 0.06% 299
2022
Q2 		$4.35M Buy
198,314
+59,027
+42% +$1.37M 0.05% 340
2022
Q1 		$6.25M Buy
139,287
+330
+0.2% +$13.6K 0.06% 288
2021
Q4 		$5.96M Buy
138,957
+67,582
+95% +$3.53M 0.06% 299
2021
Q3 		$4.75M Buy
71,375
+1,935
+3% +$136K 0.05% 340
2021
Q2 		$5.09M Sell
69,440
-14,909
-18% -$985K 0.05% 326
2021
Q1 		$5.77M Buy
84,349
+18,087
+27% +$1.36M 0.06% 312
2020
Q4 		$4.45M Sell
66,262
-1,207
-2% -$65.4K 0.05% 314
2020
Q3 		$3.47M Buy
+67,469
New +$3M 0.05% 308

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Segall Bryant & Hamill's CSTL Position: Q4 2022 in Review

Segall Bryant & Hamill sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 202,344 shares — an estimated $5.28M sold.

Segall Bryant & Hamill first reported a position in CSTL in Q3 2020 and held it in 9 quarters. The position peaked at $6.25M in Q1 2022. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Segall Bryant & Hamill reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Segall Bryant & Hamill sold 202,344 Castle Biosciences shares in Q4 2022, an estimated $5.28M.
  • Segall Bryant & Hamill first reported a position in Castle Biosciences in Q3 2020 and held it in 9 quarters.
  • Segall Bryant & Hamill's Castle Biosciences position peaked at $6.25M in Q1 2022.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Segall Bryant & Hamill's 13F filing for Q4 2022, filed 14 Feb 2023.